MQB Partners is a global healthtech investment management firm. Our team originates, invests and manages healthtech investments globally for our clients. Our firm is founded by successful entrepreneurs and investors from the healthcare and technology sectors with an impressive track record of success in investment and execution.
External link for MQB Partners
Congratulations Cerevance team for the achievement of the 2nd milestone on the research collaboration with Merck!
We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying potential novel therapeutic targets for patients with Alzheimer’s disease. A huge thank you to our dedicated team and partners at Merck for their hard work and commitment to excellence. Read the press release here: https://lnkd.in/eFFxkMgH
Congratulations Cerevance team for reaching the first milestone in your research collaboration with Merck, focusing on the identification of novel therapeutic targets for Alzheimer’s disease.
We achieved the first milestone in our research collaboration with Merck and continue our mission of identifying novel therapeutic targets for patients with Alzheimer’s disease. Read the full press release here: https://lnkd.in/gcrbkEXB
MQB Partners reposted this
MQB Partners is excited to be joining the outstanding team Cerevance on their journey to develop precision CNS medicines to treat neurological disorders. We look forward to the day that the lives of people diagnosed with Parkinson’s or other devastating neurological diseases are transformed by novel first-in-class medicines such as those in the Cerevance pipeline. Marko Bogoievski Scott McPhee Ken Chin Campbell Murray Craig Thompson Johnna Simōes Rob Middlebrook
Boston US life science company Cerevance, which has facilities at Cambridge Science Park, has taken its Series B-1 round to a stunning $98 million after securing a $47m extension. https://lnkd.in/ezZE83FU Proceeds will support an upcoming Phase 3 clinical trial for CVN424, a first-in-class non-dopamine therapy for patients with Parkinson’s disease, plus the advancement of a pipeline of novel treatments for other CNS disorders. These include Alzheimer’s disease, Amyotrophic lateral sclerosis and frontotemporal dementia. The latest financing has been led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures, with participation from new investors MQB Partners and LifeRock Ventures and existing backers Gates Frontier, GV (Google Ventures) and Lightstone Ventures. Campbell Murray, Partner at Agent Capital, and Kouki Harasaki, PhD Harasaki – Founder and Managing Partner at Bioluminescence Ventures – have joined the Cerevance board. “The support from new and existing investors underscores the ongoing advancements made by Cerevance,” said Cerevance CEO Craig Thompson. “This upcoming year marks a crucial phase as we embark on the Phase 3 clinical trial for our flagship therapy, CVN424, and continue in discovering innovative, precision CNS treatments that will enrich our extensive pipeline.” Campbell Murray added: “There is a clear need for groundbreaking, innovative therapies for Parkinson's disease. We are confident that Cerevance's lead program, CVN424, holds promise in delivering significant benefits to individuals. “We look forward to working with this talented management team and distinguished board of directors to further advance the development of new therapies for patients with CNS disorders." he company’s NETSseq (Nuclear Enriched Transcript Sort sequencing) platform is a powerful tool that pinpoints uniquely expressed, novel target proteins, which may be exclusive to particular brain circuits or exhibit altered expression levels in diseased brains. Cerevance has tackled one of the most significant hurdles in CNS drug discovery – the identification of novel, highly specific targets – and devised a clinically proven approach for target discovery and subsequent drug development.
MQB Partners reposted this
MQB Partners invests in $47m Series B-1 financing for Cerevance led by Agent Capital, Bioluminescence Ventures and Double Point Ventures, with existing investors, Gates Frontier and GV (Google Ventures) to advance robust clinical pipeline in CNS diseases. Campbell Murray Marko Bogoievski Scott McPhee Ken Chin Craig Thompson Rob Middlebrook MQB Partners
We are pleased to announce the addition of $47M to our Series B-1 Extension! These funds will advance CVN424, our first-in-class, non-dopamine therapy for the treatment of Parkinson’s into a Phase 3 clinical trial. Furthermore, they will support our robust pipeline of precision CNS treatments. To learn more, read our press release: https://lnkd.in/g-TyntMw